Table 4.
Multivariate Cox regression analysis on femoral MBD dataset.
| Explanatory variables | β Regression Coefficient | Hazard Ratio (HR) | 95% CI | P-value |
|---|---|---|---|---|
| Slow growth cancer type | −0.753 ± 0.251 | 0.47 | 0.29–0.77 | 0.003 |
| Visceral metastases | 0.648 ± 0.245 | 1.91 | 1.18–3.09 | 0.008 |
| Femoral neck lesion | 0.576 ± 0.217 | 1.78 | 1.16–2.72 | 0.008 |
| ASA > 3 | 0.551 ± 0.224 | 1.74 | 1.12–2.69 | 0.014 |
| ALP > 129 U/L | 0.638 ± 0.214 | 1.89 | 1.24–2.88 | 0.003 |
| Albumin < 30 g/L | 0.560 ± 0.225 | 1.75 | 1.13–2.72 | 0.013 |
ASA, American Society of Anesthesiologists score; ALP, alkaline phosphatase.
Slow growth type cancer included hormone-dependent breast and prostate, thyroid, multiple myeloma and lymphoma.
Variables found to be non-significant in multivariate analysis are not shown. These include: Operation at time of diagnosis, ECOG>3, pre-operative pleural effusion, CCI > 8, Haemoglobulin <120g/L and Platelets <100 × 109/L).
Both ‘Rapid growth cancer type’ and ‘Slow growth cancer type’ variables are representative of the underlying tumour type and upon including the ‘Rapid growth cancer type’ variable we observed that ‘Slow growth cancer type’ was no longer significant. We opted to omit ‘Rapid growth cancer type’ and include ‘Slow growth cancer type’ as a variable in the multivariate analysis in order to aid the interpretability of the model.
These values are given as the β coefficient and standard error.
These values are given as the Hazard Ratio (HR) with the following column the corresponding 95% confidence interval (CI).
These p-values were significant and had a two tailed p-value <0.05.